Life Science Sweden´s international issue is on its way

A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

Logos - global language service provider to the life sciences industry

The Oresund region aims at becoming Europe’s microbiome Mecca

The Medicon Valley Alliance’s ambition: Skåne and the Copenhagen region will become world leaders in microbiome research.

KI’s new President: “We need to work closer together”

A closer link between research and education and a stronger “we-feeling” are aims that Annika Östman Wernerson sets out to achieve as the new President of Karol...

Automated dispensing

Are you interested in automated dispensing of liquids?

Pilots want to live too

Helena Strigård: The rise of the community

Sweden Bio´s CEO is looking back at the last decade of development in the industry. Something has shifted in the interdependence between small and larger companies.

Pharma-on-Demand

Make or buy? That is the question that the pharma world has been asking more and more in the last couple of decades. Pernille Hemmingsen is moderator at Pharma ...

Krönika: Collaboration across borders

The perfect formula for decision-making

No one has the luxury not to take a decision, writes Helena Strigård at Swedenbio.

Rapid developments in AI – “All stakeholders are struggling to understand it”

Artificial intelligence is being discussed more and more, and developments in the field are moving rapidly. As the Swedish Medical Products Agency testifies, ke...

From spin-off to phase II

”The people there will basically become your new colleagues” – Carina Schmidt, former CEO of Athera, about working with different contractors.

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...

Astra Zeneca fick Swecares exportpris – ”Fenomenalt stark utveckling”

Ett globalt storbolag och en uppstickare delar på Swecare Export Awards 2024. Årets vinnare: läkemedelsjätten Astra Zeneca och sårvårdsbolaget PU sensor.

Brexit creeping closer – or?

In this column, lawyer Pernilla Norman, tries to sort out the different Brexit options.

Novo Nordisk invests billions in expanding its production capacity

Danish pharmaceutical company Novo Nordisk is making a major investment to develop and expand its production facility in Hillerød, north of Copenhagen. DKK 15.9...

Anna Törner: To kill your darlings

Förhoppningarna var höga när Anna Törner och hennes kollega startade en studie om ett kosttillskott som verkade vara overkligt bra. "Entusiastiskt drömde vi om ...

Study: Semaglutide tablet produces weight loss

The pharmaceutical semaglutide is effective for weight loss even when given in tablet form, according to a phase 3 study.

Norwegian company wins bidding battle for Sensidose

The lengthy battle to acquire medical device company Sensidose is apparently over. Generic medicines company EQL Pharma is pulling out, selling its shares and l...

Webinar: How to Plan And Analyze a Real-World Evidence Study

This webinar is for drug developers who want to understand the basic ideas of analyzing an RWE study, as well as avoiding the most common pitfalls.

Webinar: Clinical evaluation and clinical investigation of medical devices

Whether you are a small medtech company or a large one, this webinar is a must-attend for anyone curious about how clinical studies on medical devices are conducted.

Nocebo – den onda tvillingen som får dig att må sämre

Placeboeffekten är väl känd inom vården – men det gäller inte dess motsats: nocebo. "Det är en liten effekt, men den kan få stora återverkningar", säger Uppsala...

A surprising discovery about the immune system in cases of cancer

Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising d...